558 related articles for article (PubMed ID: 28843359)
21. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925
[TBL] [Abstract][Full Text] [Related]
22. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
Liu Y; Lai M; Li S; Wang Y; Feng F; Zhang T; Tong L; Zhang M; Chen H; Chen Y; Song P; Li Y; Bai G; Ning Y; Tang H; Fang Y; Chen Y; Lu X; Geng M; Ding K; Yu K; Xie H; Ding J
Cancer Sci; 2022 Feb; 113(2):709-720. PubMed ID: 34855271
[TBL] [Abstract][Full Text] [Related]
23. [Osimertinib (Tagrisso
Giroux Leprieur E; Cortot AB; Cadranel J; Wislez M
Bull Cancer; 2016 Oct; 103(10):815-821. PubMed ID: 27641462
[TBL] [Abstract][Full Text] [Related]
24. Molecular follow-up of first-line treatment by osimertinib in lung cancer: Importance of using appropriate tools for detecting EGFR resistance mutation C797S.
Fanjat Y; Barazzutti H; Di Mauro I; Tabary-Martin L; Duranton-Tanneur V; Gimet S; Bérard H; Pedeutour F
Cancer Genet; 2021 Aug; 256-257():158-161. PubMed ID: 34157597
[TBL] [Abstract][Full Text] [Related]
25. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
Wang Y; Yang N; Zhang Y; Li Li ; Han R; Zhu M; Feng M; Chen H; Lizaso A; Qin T; Liu X; He Y
J Thorac Oncol; 2020 Aug; 15(8):1369-1375. PubMed ID: 32353596
[TBL] [Abstract][Full Text] [Related]
26. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
28. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.
Gao X; Le X; Costa DB
Expert Rev Anticancer Ther; 2016; 16(4):383-90. PubMed ID: 26943236
[TBL] [Abstract][Full Text] [Related]
29. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.
Jenkins S; Yang JC; Jänne PA; Thress KS; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd FA
J Thorac Oncol; 2017 Aug; 12(8):1247-1256. PubMed ID: 28527899
[TBL] [Abstract][Full Text] [Related]
30. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
Lim SM; Fujino T; Kim C; Lee G; Lee YH; Kim DW; Ahn JS; Mitsudomi T; Jin T; Lee SY
Clin Cancer Res; 2023 Aug; 29(16):3004-3016. PubMed ID: 37249619
[TBL] [Abstract][Full Text] [Related]
31. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.
Li C; Jia R; Liu H; Zhang B; Wang C
Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780
[TBL] [Abstract][Full Text] [Related]
32. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.
McCoach CE; Jimeno A
Drugs Today (Barc); 2016 Oct; 52(10):561-568. PubMed ID: 27910964
[TBL] [Abstract][Full Text] [Related]
33. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K
Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198
[TBL] [Abstract][Full Text] [Related]
34. The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
Remon J; Menis J; Hasan B; Peric A; De Maio E; Novello S; Reck M; Berghmans T; Wasag B; Besse B; Dziadziuszko R
Clin Lung Cancer; 2017 Sep; 18(5):583-588. PubMed ID: 28341106
[TBL] [Abstract][Full Text] [Related]
35. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
Sullivan I; Planchard D
Ther Adv Respir Dis; 2016 Dec; 10(6):549-565. PubMed ID: 27784815
[TBL] [Abstract][Full Text] [Related]
36. Reprogramming Tumor-Associated Macrophages To Reverse EGFR
Peng H; Chen B; Huang W; Tang Y; Jiang Y; Zhang W; Huang Y
Nano Lett; 2017 Dec; 17(12):7684-7690. PubMed ID: 29160717
[TBL] [Abstract][Full Text] [Related]
37. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M
Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257
[TBL] [Abstract][Full Text] [Related]
38. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C; Cadranel J; Rousseau-Bussac G; Lacave R; Pujals A; Girard N; Callens C; Gounant V; Théou-Anton N; Friard S; Trédaniel J; Blons H; Dujon C; Duchemann B; Schischmanoff PO; Chinet T; Giroux Leprieur E
Lung Cancer; 2019 Nov; 137():149-156. PubMed ID: 31600593
[TBL] [Abstract][Full Text] [Related]
39. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.
Rossi A; Muscarella LA; Di Micco C; Carbonelli C; D'alessandro V; Notarangelo S; Palomba G; Sanpaolo G; Taurchini M; Graziano P; Maiello E
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1281-1288. PubMed ID: 29095090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
